DELCATH SYSTEMS, INC. (DCTH): Results of Operations and Financial Condition
DELCATH SYSTEMS, INC. (DCTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Delcath Systems Reports Second Quarter 2026 Results and Business Highlights Increases 2026 Revenue Guidance to a Range of $104M to $108M Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, NY – August 6, 2026, Delcath Systems, Inc. (Nasdaq: DCTH), an interven
How this was made
The 30-second read
Why it matters
Traders can reprice DCTH based on the raised 2026 revenue range ($104M-$108M) and the stated driver of at least 28% HEPZATO KIT volume growth over 2025, alongside Q2 operating cash flow and cash balance.
Market read
A company-specific earnings and guidance update with explicit full-year revenue and margin ranges, plus operational metrics (treatment centers, HEPZATO volume growth).
What to watch
R&D and SG&A both rose in Q2, and the filing does not provide updated trial endpoints beyond dosing and retrospective presentations, which may limit upside if investors demand prospective efficacy data.
Background
SEC 8-K Item 2.02 with Exhibit 99.1 covering Delcath’s Q2 2026 results, business highlights, and full-year 2026 financial guidance.
Ticker impact
Delcath reported Q2 revenue of $29.1M, raised 2026 guidance to $104M-$108M, and reiterated positive adjusted EBITDA outlook.
Likely positive bias for the next session and into guidance digestion, with focus on whether HEPZATO volume growth sustains.
The filing discloses fresh, decision-relevant numbers: Q2 revenue and margins, cash balance, and a full-year revenue range tied to at least 28% HEPZATO KIT volume growth over 2025.
Market effects
Reinforces investor appetite for interventional oncology and liver-directed delivery platforms, potentially supporting peer sentiment.
Primarily US small-cap biotech sentiment; limited direct regional spillover beyond healthcare.
Europe device revenue contribution is mentioned, but the disclosed catalyst is company-specific rather than global policy or trial readout.
Counterpoint
Adjusted EBITDA declined year over year (to $7.6M from $9.8M), so the market may question whether guidance relies on volume growth that is not yet translating into profitability.
Key entities
- companyDelcath Systems, Inc.
Interventional oncology company reporting Q2 2026 results and raising full-year 2026 revenue guidance.
- productHEPZATO KIT
Primary revenue driver in the US, with reported Q2 revenue of $27.1M and guidance tied to volume growth.
- productCHEMOSAT
Europe revenue contributor, with reported Q2 revenue of $2.0M.
